Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SRRK
stocks logo

SRRK

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
8 Analyst Rating
up Image0
Wall Street analysts forecast SRRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRRK is 50.33 USD with a low forecast of 46.00 USD and a high forecast of 57.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 40.720
sliders
Low
46.00
Averages
50.33
High
57.00
up Image0
Current: 40.720
sliders
Low
46.00
Averages
50.33
High
57.00
Cantor Fitzgerald
initiated
2025-07-17
New
Reason
Cantor Fitzgerald
Price Target
2025-07-17
New
initiated
Reason
Cantor Fitzgerald initiated coverage of Scholar Rock with an Overweight rating.
JPMorgan
Overweight
maintain
$46
2025-06-26
Reason
JPMorgan
Price Target
$46
2025-06-26
maintain
Overweight
Reason
HC Wainwright & Co.
Andres Maldonado
Strong Buy
Maintains
$40 → $50
2024-11-26
Reason
HC Wainwright & Co.
Andres Maldonado
Price Target
$40 → $50
2024-11-26
Maintains
Strong Buy
Reason
Truist Securities
Srikripa Devarakonda
Strong Buy
Maintains
$36 → $45
2024-11-25
Reason
Truist Securities
Srikripa Devarakonda
Price Target
$36 → $45
2024-11-25
Maintains
Strong Buy
Reason
Truist raised the firm's price target on Scholar Rock (SRRK) to $45 from $36 and keeps a Buy rating on the shares after Biohaven's Phase 3 study spinal muscular atrophy failed to meet the primary endpoint. Truist now sees a stronger case for Scholar Rock in SMA and are increased its peak sales to $1.5B from $1.2B. The SMA market opportunity could be larger than anticipated given the removal of this competitive overhang, the analyst tells investors in a research note. With positive SMA data and apitegromab in a Phase 2 trial for obesity, the firm now sees Scholar Rock as a potential takeout target.
Wedbush
David Nierengarten
Buy
Maintains
$40 → $47
2024-11-25
Reason
Wedbush
David Nierengarten
Price Target
$40 → $47
2024-11-25
Maintains
Buy
Reason
Wedbush raised the firm's price target on Scholar Rock (SRRK) to $47 from $40 and keeps an Outperform rating on the shares. Biohaven's (BHVN) trial miss leaves Scholar Rock's apitegromab as the only agent in the class likely to gain approval in the near-term in spinal muscular atrophy, the analyst tells investors in a research note. The firm now anticipates greater market penetration with Scholar Rock's treatment with a launch possible as early as Q4 of 2025.
HC Wainwright & Co.
Andres Maldonado
Strong Buy
Maintains
$35 → $40
2024-11-12
Reason
HC Wainwright & Co.
Andres Maldonado
Price Target
$35 → $40
2024-11-12
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Scholar Rock Holding Corp (SRRK.O) is -15.65, compared to its 5-year average forward P/E of -7.68. For a more detailed relative valuation and DCF analysis to assess Scholar Rock Holding Corp 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.68
Current PE
-15.65
Overvalued PE
-3.02
Undervalued PE
-12.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.76
Current EV/EBITDA
-13.31
Overvalued EV/EBITDA
1.64
Undervalued EV/EBITDA
-7.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
26.07
Current PS
205.20
Overvalued PS
67.44
Undervalued PS
-15.30

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

SRRK News & Events

Events Timeline

(ET)
2025-06-18
07:05:15
Scholar Rock announces results from EMBRAZE trial
select
2025-06-13 (ET)
2025-06-13
11:49:43
Jefferies sees Akero, Scholar Rock as 'promising' takeover targets
select
2025-06-02 (ET)
2025-06-02
08:19:38
Scholar Rock appoints McLeod as Chief Brand Officer, U.S. General Manager
select
Sign Up For More Events
Sign Up For More Events

News

Preview
5.0
07-19Yahoo Finance
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Scholar Rock's Inducement Awards: Scholar Rock has granted inducement equity awards totaling 224,100 shares to six new employees, including stock options and restricted stock units, as part of their 2022 Inducement Equity Plan.

  • Company Overview: Scholar Rock is a biopharmaceutical company focused on developing therapies for serious diseases, particularly in neuromuscular disorders, utilizing a proprietary platform to create targeted monoclonal antibodies.

Preview
6.5
07-03CNBC
These are JPMorgan’s favorite stocks heading into July

  • JPMorgan's Stock Picks: JPMorgan has added biotechnology firm Scholar Rock and construction supplies company Carlisle Companies to its top stock picks for July, while removing Vera Therapeutics and Alarm.com from the list. The updates come as U.S. stocks reached record highs in the first half of 2025.

  • Performance and Price Targets: Scholar Rock's shares have seen an 18% decline year-to-date but recently reported positive trial results, with a price target of $46 indicating a potential 29% upside. Carlisle Companies has gained about 7% in 2025, with a price target of $500 suggesting a 26% upside from its current price.

Preview
9.0
06-21Reuters
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

  • Market Potential for Muscle-Preserving Therapies: Analysts predict that muscle-preserving treatments associated with obesity drugs from Eli Lilly and Novo Nordisk could generate over $30 billion in sales by 2035, driven by the need to maintain muscle mass while losing weight.

  • Regulatory Challenges and Drug Development: The first muscle-preserving treatment is expected to launch by 2028, but must demonstrate additional health benefits to gain regulatory approval, as concerns about muscle loss linked to existing obesity drugs persist among healthcare professionals.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Scholar Rock Holding Corp (SRRK) stock price today?

The current price of SRRK is 40.72 USD — it has decreased -4.99 % in the last trading day.

arrow icon

What is Scholar Rock Holding Corp (SRRK)'s business?

Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.

arrow icon

What is the price predicton of SRRK Stock?

Wall Street analysts forecast SRRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRRK is 50.33 USD with a low forecast of 46.00 USD and a high forecast of 57.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Scholar Rock Holding Corp (SRRK)'s revenue for the last quarter?

Scholar Rock Holding Corp revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Scholar Rock Holding Corp (SRRK)'s earnings per share (EPS) for the last quarter?

Scholar Rock Holding Corp. EPS for the last quarter amounts to -0.67 USD, increased 13.56 % YoY.

arrow icon

What changes have occurred in the market's expectations for Scholar Rock Holding Corp (SRRK)'s fundamentals?

The market is revising Downward the revenue expectations for Scholar Rock Holding Corporation (SRRK) for FY2025, with the revenue forecasts being adjusted by -73.09% over the past three months. During the same period, the stock price has changed by 36.60%.
arrow icon

How many employees does Scholar Rock Holding Corp (SRRK). have?

Scholar Rock Holding Corp (SRRK) has 196 emplpoyees as of July 20 2025.

arrow icon

What is Scholar Rock Holding Corp (SRRK) market cap?

Today SRRK has the market capitalization of 3.87B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free